Schulhoff & Co. Inc. Invests $2.10 Million in Avadel Pharmaceuticals PLC. $AVDL

Schulhoff & Co. Inc. bought a new stake in Avadel Pharmaceuticals PLC. (NASDAQ:AVDL) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 137,500 shares of the company’s stock, valued at approximately $2,100,000. Schulhoff & Co. Inc. owned 0.14% of Avadel Pharmaceuticals at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in AVDL. Vanguard Group Inc. lifted its holdings in Avadel Pharmaceuticals by 0.8% in the 3rd quarter. Vanguard Group Inc. now owns 5,606,282 shares of the company’s stock worth $85,608,000 after buying an additional 42,023 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in shares of Avadel Pharmaceuticals by 405.4% in the third quarter. JPMorgan Chase & Co. now owns 565,471 shares of the company’s stock worth $8,635,000 after acquiring an additional 453,582 shares in the last quarter. Baader Bank Aktiengesellschaft acquired a new position in shares of Avadel Pharmaceuticals in the third quarter worth about $229,000. Profund Advisors LLC purchased a new position in Avadel Pharmaceuticals in the third quarter valued at about $248,000. Finally, RFG Advisory LLC acquired a new stake in Avadel Pharmaceuticals during the 3rd quarter valued at approximately $1,129,000. Hedge funds and other institutional investors own 69.19% of the company’s stock.

Avadel Pharmaceuticals Trading Down 1.1%

Shares of NASDAQ AVDL opened at $21.39 on Monday. Avadel Pharmaceuticals PLC. has a twelve month low of $6.38 and a twelve month high of $23.57. The business has a 50 day simple moving average of $21.51 and a 200-day simple moving average of $18.73.

Analyst Ratings Changes

AVDL has been the topic of a number of recent analyst reports. Wells Fargo & Company upped their target price on Avadel Pharmaceuticals from $20.00 to $22.50 and gave the company an “equal weight” rating in a research report on Thursday, November 20th. Weiss Ratings restated a “sell (d-)” rating on shares of Avadel Pharmaceuticals in a research note on Monday, December 29th. Zacks Research raised shares of Avadel Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Tuesday, January 6th. Finally, UBS Group lowered shares of Avadel Pharmaceuticals to a “neutral” rating in a report on Tuesday, October 28th. One equities research analyst has rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $20.00.

Avadel Pharmaceuticals Profile

Avadel Pharmaceuticals plc is a global specialty biopharmaceutical company focused on developing and delivering treatments for rare diseases and central nervous system disorders. Headquartered in Dublin, Ireland, with operations in the United States, Avadel’s portfolio centers on sleep disorder therapeutics, including its flagship low-sodium oxybate product, XYWAV, which is approved in the U.S. for the treatment of cataplexy or excessive daytime sleepiness in patients with narcolepsy. The company is also advancing FT218, a once-nightly formulation of sodium oxybate, currently under regulatory review for narcolepsy management.

Formed through a rebranding of Flamel Technologies in 2016 and a strategic shift toward rare disease drug development, Avadel has built its R&D capabilities around improving patient compliance and reducing daily sodium exposure compared to traditional therapies.